💊 Clopidogrel

Clopidogrel is an antiplatelet agent belonging to the thienopyridine class. It is a prodrug that inhibits platelet aggregation.

Clopidogrel is a prodrug that requires hepatic metabolism by cytochrome P450 enzymes (primarily CYP2C19) to its active metabolite. This active metabolite irreversibly blocks the P2Y12 adenosine diphosphate (ADP) receptor on the surface of platelets. Blocking this receptor prevents ADP-mediated activation of the glycoprotein IIb/IIIa complex, thereby inhibiting platelet aggregation.

Clopidogrel is used for the prevention of atherothrombotic events in patients with a history of myocardial infarction, ischaemic stroke, or established peripheral arterial disease. It is also indicated, often in combination with aspirin (dual antiplatelet therapy - DAPT), for acute coronary syndromes (unstable angina, NSTEMI, STEMI) and following percutaneous coronary intervention (PCI) with stent placement.

Absolute contraindications include active pathological bleeding, such as peptic ulcer or intracranial haemorrhage. Severe hepatic impairment is also a contraindication. Caution is advised in patients at increased risk of bleeding, including those with a history of GI bleeding or trauma, and those undergoing surgery.

Common adverse effects include bleeding, ranging from minor bruising to serious haemorrhage. Gastrointestinal disturbances such as abdominal pain, dyspepsia, and diarrhoea can occur. Skin rashes are also reported. Rarely, serious side effects include thrombotic thrombocytopenic purpura (TTP) and agranulocytosis.

No routine blood monitoring is typically required for clopidogrel. Patients should be monitored for signs of bleeding, particularly during the initial weeks of treatment or when co-administered with other antiplatelet or anticoagulant agents. Liver function tests may be considered in patients with pre-existing hepatic impairment.

When prescribing, always check for active bleeding and a history of bleeding disorders. Be aware of drug interactions, particularly with proton pump inhibitors (PPIs) like omeprazole (due to CYP2C19 inhibition, potentially reducing clopidogrel's efficacy), and other antiplatelet agents or anticoagulants. Counsel patients on the increased risk of bleeding and to report any unusual bruising or bleeding.

Clopidogrel's irreversible P2Y12 receptor blockade is crucial. The prodrug nature and CYP2C19 metabolism are high-yield facts. Understand its role in DAPT for ACS and post-PCI, and the importance of adhering to treatment duration. Remember the bleeding risk and the rare but serious TTP. Genetic variations in CYP2C19 can impact its effectiveness.

SBA questions frequently test the concept of clopidogrel as a prodrug and the role of CYP2C19 in its activation, particularly genetic polymorphisms affecting efficacy. Its use in DAPT following PCI and the duration of this therapy is a common theme. Questions might also focus on its contraindications, especially active bleeding, and the risk of TTP.